{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"Participants with mixed cellularity histologic subtype in HIV-HL in the HAART era","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG000","title":"Phase I - Brentuximab 1.2 mg/kg"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG001","title":"Phase II - Brentuximab 1.2 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Characterization of Histologic Subtypes in HIV-HL in the HAART Era","type":"SECONDARY","unitOfMeasure":"Participants"}